Description
8-Week Total Recovery System
A complete nine-vial research protocol pairing three complementary compounds — tissue-repair peptides, a dual-pathway growth-hormone secretagogue, and the cellular coenzyme NAD+ — to address recovery structurally, hormonally, and at the cellular level across a full eight-week arc.
§ 01 — The System
Recovery is not one problem — so this is not one compound.
| Real tissue recovery unfolds on three fronts at once: the structure has to be rebuilt, the signal to grow has to be present, and the cells doing the work have to be fully powered. Addressing only one of those leaves the process under-resourced. This system supplies all three, together, across an eight-week arc.
The Wolverine Blend drives structural repair. The CJC-1295 / Ipamorelin stack amplifies growth-hormone and IGF-1 signaling. NAD+ fuels the energy-intensive cellular machinery behind both. Every vial is research-grade, HPLC-verified above ninety-nine percent purity, and lot-verified for reproducible protocol work. |
Tissue repair is energy-expensive and hormone-dependent. Giving repair peptides without the cellular fuel and anabolic signaling to support them is like framing a house with no power to the site.
|
§ 02 — The Three Pillars
Three compounds, nine vials — each covering what the others cannot.
×3 · Wolverine Blend
Structural Repair10 mg BPC-157 + 10 mg TB-500 BPC-157 drives localized repair — angiogenesis, growth-factor signaling, and tendon, ligament, and gut tissue healing. TB-500 (thymosin β-4 fragment) works systemically, mobilizing repair cells and remodeling actin. One builds the repair infrastructure; the other moves the crew into position. |
×3 · CJC-1295 / Ipamorelin
Growth Signal5 mg CJC-1295 + 5 mg Ipamorelin A GHRH analog paired with a selective ghrelin mimetic, stimulating growth hormone through two pathways at once for a larger, cleaner pulse. The resulting GH → IGF-1 rise drives protein synthesis, collagen turnover, connective-tissue repair, and improved sleep — without raising cortisol or prolactin. |
×3 · NAD+
Cellular Fuel500 mg per vial The coenzyme at the center of mitochondrial ATP production, DNA repair, and sirtuin signaling. NAD+ powers the energy-intensive repair cascade the other two compounds initiate — and its levels fall exactly when recovery demand is highest. |
§ 03 — Why All Three
A single cascade — four steps, three compounds, one outcome.
i
Repair the StructureBPC-157 and TB-500 lay down new blood vessels and migrate repair cells into damaged tendon, ligament, muscle, and soft tissue. |
ii
Signal the GrowthThe GH/IGF-1 pulse from CJC-1295 / Ipamorelin drives protein synthesis and collagen deposition — turning repair signaling into actual tissue. |
iii
Fuel the ProcessNAD+ sustains the mitochondrial energy and DNA-repair capacity that every step above depends on — the power behind the machinery. |
iv
Compound the EffectRun together over eight weeks, the three layers reinforce one another — structural, hormonal, and cellular recovery advancing in parallel rather than sequence. |
✦
On Layering
The rationale for a system over a single compound is coverage. Repair peptides supply the blueprint, GH/IGF-1 supplies the anabolic drive, and NAD+ supplies the energy — three non-overlapping pieces of the same recovery problem. Addressed together, each amplifies the return on the others; addressed alone, each runs into the ceiling the other two would have lifted.
§ 04 — Research Applications
Primary subjects of investigation — strictly laboratory use.
A.01
Soft-Tissue RepairStudies of tendon, ligament, muscle, and gut healing under combined local and systemic repair-peptide signaling. |
A.02
Recovery & SleepResearch into GH/IGF-1-mediated recovery, sleep architecture, and overnight tissue restoration. |
A.03
Connective TissueInvestigating collagen synthesis, joint and tendon integrity, and the anabolic support of structural remodeling. |
A.04
Cellular ResilienceExamining NAD+-dependent mitochondrial energy and DNA-repair capacity as the metabolic floor for recovery. |
§ 05 — Scientific References
Peer-reviewed literature supporting the components of this system.
| i. |
BPC-157 & Tendon RepairPreclinical research reporting that BPC-157 accelerates tendon-to-bone and ligament healing through angiogenesis and growth-factor pathway activation — the localized half of the Wolverine repair signal. |
View on PubMed → |
| ii. |
Thymosin β-4 & Cell MigrationFoundational studies characterizing the actin-binding domain of thymosin β-4 (TB-500) and its role in cell migration, angiogenesis, and anti-fibrotic tissue organization — the systemic half of the repair response. |
View on PubMed → |
| iii. |
GHRH + Ghrelin Pathway SynergyResearch demonstrating that co-stimulating the GHRH and ghrelin receptors yields a greater growth-hormone response than either pathway alone — the basis for pairing CJC-1295 with ipamorelin. |
View on PubMed → |
| iv. |
Age-Related Decline of NAD+A foundational study showing tissue NAD+ levels fall substantially with age and metabolic demand, with measurable consequences for mitochondrial function and repair capacity — the rationale for cellular-energy support. |
View on PubMed → |
§ 06 — Kit Contents & Specifications
Certificate of analysis available upon request for each compound.
| System | 8-Week Total Recovery System · 9 vials |
| Wolverine Blend ×3 | 20 mg each · 10 mg BPC-157 + 10 mg TB-500 |
| CJC-1295 / Ipamorelin ×3 | 10 mg each · 5 mg CJC-1295 (no DAC) + 5 mg Ipamorelin |
| NAD+ ×3 | 500 mg each · β-Nicotinamide Adenine Dinucleotide |
| Format | Lyophilized Powder (Freeze-dried) |
| Purity | > 99% (HPLC Verified) |
| Storage — Unreconstituted | Store at −20°C · Protect from light |
| Storage — Reconstituted | Refrigerate at 2–8°C · Use within ~28 days · Do not freeze |
| Reconstitution | Bacteriostatic Water |
Research Use OnlyAll products listed are intended exclusively for laboratory research and development purposes. They are not intended for human consumption, diagnostic, or therapeutic use. Customers must be at least 21 years of age to purchase.
Reviews
There are no reviews yet.